Drug repurposing is attracting growing attention as a strategy to address unmet medical needs by identifying new uses for existing medicines. Against this backdrop, the Reagan-Udall Foundation for the FDA,…
Drug repurposing is attracting growing attention as a strategy to address unmet medical needs by identifying new uses for existing medicines. Against this backdrop, the Reagan-Udall Foundation for the FDA,…
REMEDi4ALL and iDR26 features in a RARE Revolution insider piece on “Drug repurposing: translating optimism into action for rare diseases” highlighting discussions at the conference and outlining ongoing hurdles related to realising the full potential of drug repurposing.
Prof. Zoltán Kaló, co-founder of REMEDi4ALL partner organisation Syreon Research Institute, has been appointed Director General of Hungary’s National Health Insurance Fund, taking up a senior leadership position within the newly formed Hungarian Government. Prof….
REMEDi4ALL and iDR26 features in a RARE Revolution insider piece on “Drug repurposing: translating optimism into action for rare diseases” highlighting discussions at the conference and outlining ongoing hurdles related to realising the full potential of drug repurposing.
REMEDi4ALL features in a Reader’s Digest piece on “How AI is saving lives: Artificial intelligence can find new uses for existing drugs, helping to treat rare diseases, including the one that almost killed Joseph Coates” with an interview from REMEDi4ALL Scientific Coordinator Donald Lo.
This Forbes article highlights iDR25 (the International Drug Repurposing Conference) and the growing potential of drug repurposing to expand treatment possibilities in rare diseases.
REMEDi4ALL features in an article republished in The Age (Melbourne, Australia) on the power of AI in drug repurposing with an interview from REMEDi4ALL Scientific Coordinator Donald Lo.
El País covers highlights the promise of Drug Repurposing and the REMEDi4ALL project (French translation).
El País covers highlights the promise of Drug Repurposing and the REMEDi4ALL project (Spanish version).
REMEDi4ALL features in a New York Times article on the power of AI in drug repurposing with an interview from REMEDi4ALL Scientific Coordinator Donald Lo.
REMEDi4ALL partner Beacon for Rare Diseases featured in Mediaplanet’s Rare Disease Day campaign – both online and in print.
In the piece, Beacon CEO Rick Thompson highlighted the power of multistakeholder collaborations like REMEDi4ALL, in accelerating the delivery of much-needed treatments to rare disease patients.
El País covers highlights the promise of Drug Repurposing and the REMEDi4ALL project (English version).